Effects of Berries and Vegetables on Cardiometabolic Risk Markers and Cognitive Functions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01562392 |
Recruitment Status :
Completed
First Posted : March 23, 2012
Last Update Posted : February 27, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metabolic Syndrome Inflammation Aging Fermentation | Dietary Supplement: berries and vegetables Dietary Supplement: control product | Not Applicable |
The metabolic syndrome (MetS) includes a cluster of dysfunctions that identifies subjects at risk of developing type-2 diabetes and cardiovascular disease (CVD). A key feature appears to be chronic increased inflammation and activation of the innate system. Consequently, increased low-grade inflammation has been connected to adverse effects on insulin sensitivity, glucose- and lipid metabolism, and blood pressure, and circulating markers of inflammation such as IL-6. A growing body of evidence also link low-grade inflammation to poorer cognitive functioning. Type 2 diabetes, MetS, and glucose intolerance are increasingly being associated with impaired cognition.
Dietary patterns which promote sub-clinical inflammation are increasingly being considered predictive of future risk of CVD and type-2 diabetes. There is a growing insight regarding the role of the colonic micro flora in metabolic regulation and development of low-grade inflammation and obesity. The metabolic cross talk between the colon and peripheral tissues, especially adipose tissue, has been suggested to be regulated through colonic fermentation of indigestible carbohydrates e.g. dietary fibres (DF) and resistant starch. In addition, epidemiological data shows that a high consumption of vegetables and fruits is associated with a lowered risk of cancer and cardiovascular disease, which may be due to the high concentrations of polyphenols or other anti-oxidants that are found in such foods. In addition vegetables and berries are rich in dietary fibres with the potential to beneficially modulate the gut micro flora which may have implication on metabolic risk factors.
In the presently described project it is hypothesized that 5 w daily consumption of a food product containing berries and vegetables can improve metabolic risk variables and cognitive functions. The purpose is therefore to study the potential anti-inflammatory- and metabolic effects, and prebiotic properties, of a food product based on a mixture of several Swedish berries and vegetables that is known to be rich in dietary fibres, polyphenols and other anti-oxidants. In addition the purpose is to investigate the effects on cognitive functions of the food product.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Basic Science |
Official Title: | Effects of 5 w Daily Intake of Berries and Vegetables on Cardiometabolic Risk Markers and Cognitive Functions |
Study Start Date : | September 2011 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | January 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: berries and vegetables
subjects include specific berries and vegetables in the diet
|
Dietary Supplement: berries and vegetables
Daily (5 w) supplementation with specific vegetables and berries |
Placebo Comparator: control product
Control product with equivalent amounts of carbohydrates but without vegetables and berries.
|
Dietary Supplement: control product
Supplementation (daily,5 w) with a control product without berries and vegetables. |
- Working memory test [ Time Frame: 5 week after intervention with test- and control product, respectively ]Cognitive tests (i.e. working memory) will be executed repeatedly in the morning the day after completing the 5 w (35 days)intervention periods.The tests is executed in the morning after a standardised breakfast. The tests starts 30 min after start of the breakfast and are then performed repeatedly at exact time points after the standardised breakfast.The last cognitive test is executed at 150 min post breakfast.
- cardiometabolic risk variables [ Time Frame: cardiometabolic risk variables will be measured the day for start of and the morning after the 5 week (35 d) intervention periods. ]Inflammatory markers, blood lipids, glucose, insulin, satiety hormons will be determined at fasting in the morning at the first day and the day after completing 5 w (35 days)intervention periods with test product and control product, respectively.
- oxidative stress [ Time Frame: will be measured the day for start of and the morning after the 5 week (35 d) intervention periods. ]ox-LDL and MDA will be determined in blood at fasting in the morning at the first day and the day after completing 5 w (35 days)intervention periods with test product and control product, respectively.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy subjects
Exclusion Criteria:
- fasting plasma glucose >6.1
- known cognitive decline
- other medications than for treatment of hypertension or hypothyroidism known gastro- intestinal problems

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01562392
Sweden | |
Applied Nutrition and Food Chemistry, Lund University | |
Lund, Sweden, SE-22100 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Anne Nilsson, PhD, Lund University |
ClinicalTrials.gov Identifier: | NCT01562392 |
Other Study ID Numbers: |
Dnr 2010/457,2011/510 |
First Posted: | March 23, 2012 Key Record Dates |
Last Update Posted: | February 27, 2014 |
Last Verified: | February 2014 |
dietary prevention cognitive performance metabolic syndrome |
colonic fermentation sub clinical inflammation cognition and metabolism |
Metabolic Syndrome Inflammation Pathologic Processes Insulin Resistance |
Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |